In 2023, the Hong Kong Stock Exchange's 18A segment celebrated its fifth year of listing, and the fifth set of standards for the Sci-Tech Innovation Board welcomed its fourth year of operation. A total of 85 biotech companies have successfully gone public through this listing channel, driving the entire life sciences sector into high gear. Having experienced both a boom and a frenzy, as well as a cold winter and rationality, life sciences companies have never stopped innovating and breaking through. They continuously inject development momentum through technological innovation and bridge gaps through business model innovation. After experiencing dark moments, they can still be seen standing at new starting points and forging ahead with determination.
From September 27th to 28th, Frost & Sullivan's (Frost & Sullivan, abbreviated as: Frost & Sullivan) 2nd New Investment Expo and the 17th Frost & Sullivan Global Growth, Innovation and Leadership Summit (abbreviated as 'Frost & Sullivan New Investment Conference') will be grandly held at the Shangri-La Hotel in Pudong, Shanghai. The conference will introduce a number of heavyweight announcements.New Investment Summit Forum in Life Sciences, with"New Directions for the Future" &mdquo; Forge AheadFor the theme, gatherIndustry leaders, life science companies, investment institutions, and professional service providersFocusing on new investment opportunities in life sciences, we jointly explore the capital and industrial forces that enable enterprises to navigate through cycles.
We sincerely invite you to attend this forum and embark on the successful journey towards the capital market of life science enterprises!
Time:September 27 - 28, 2023
Venue:Shanghai Pudong Shangri-La Hotel
Co-organizers:Frost & Sullivan, China BIOTIC INDUSTRIAL CHAIN INNOVATION AND TRANSFORMATION ALLIANCE (CBIITA)
About Chuangjian Medical
Jiangsu Chuangjian Medical Technology Co., Ltd. is a platform-based enterprise that drives innovation in the entire synthetic biology industry chain. It owns a biosynthesis platform and a medical device transformation platform, focusing on the research, development, production, and sales of new biomaterials, innovative functional proteins, nucleic acid drugs, food raw materials, and new medical device products. It holds 5 authorized core sequence patents for recombinant collagen in the field of recombinant collagen.
The company adheres to an independent innovation development path. It has successively participated in research projects of the national '13th Five-Year Plan' and '14th Five-Year Plan', as well as several provincial and municipal research projects. It has been rated as a high-tech enterprise and has won many honors including the title of National/Provincial Specialized, Refined and Innovative 'Little Giant' Enterprise, Jiangsu Postdoctoral Innovation Base, and Jiangsu Province's Potential Unicorn Enterprise.
Introduction to the Speaker
Li Haihang, Chief Technology Officer of Jiangsu Chuangjian Medical Technology Co., Ltd. He holds a Master of Surgery from Naval Medical University, serves as Deputy Secretary-General of the Tissue Regeneration Branch of the Chinese Medical Equipment Society, a member of the 3D Printing Technology Branch of the Chinese Pharmaceutical Biotechnology Association, and a member of the Chinese Biomaterials Society. He has published over 30 academic papers and holds 4 authorized invention patents.
Specialty: Tissue regeneration and repair | Recombinant collagen
01
Participation in consultation
Registration Consultation | Business Cooperation | Media Cooperation
Contact Person:
Ms. Li, 18917935734 (WeChat ID)
Ms. Bai, 18019047843 (same as WeChat)
02
Highlights from the Previous Session
